| Disorders of bone metabolism may lead to bone metabolism-related diseases, leading to local or systemic bone diseases, such as osteoporosis, cystic fibrosis, and sarcopenia. Osteostatin, as an inhibitor, inhibits bone differentiation and bone growth through Wntβ-catenin signaling pathway. When Wnt protein is inactivated, osteostatin may combine with low density lipoprotein LPR5/6 protein, and produce a series of reactions, resulting in the reduction of osteoblasts and the increase of osteoclasts, becoming one of the inducement of bone metabolic diseases, and playing a negative role in regulating the process of bone turnover. Studies have found that sclerostatin monoclonal antibody has been regarded as a new drug in the United States. It has made certain progress in the prevention and treatment of bone metabolic diseases. By promoting bone formation, inhibiting bone resorption, and antagonizing the negative regulating effect of sclerotic statin on bone metabolism, good curative effect is obtained. However, sclerostatin monoclonal antibody is still in the phase III clinical trial stage in China, and the application of this drug in cardiovascular and cerebrovascular patients has some risks. Therefore, it has not been widely used in clinical treatment. In this paper, through studying the mechanism of action and signaling pathway, we discuss how sclerostin plays its role, and expound its clinical application scope and precautions, aiming to provide new ideas for clinical prevention and treatment of bone metabolism related diseases. |